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and Chieh-Lin Jerry Teng1,5,6Abstract
Primary splenic diffuse large B-cell lymphoma (DLBCL) is a rare clinical condition, which is generally treated by six to
eight cycles of chemotherapy involving a combination of rituximab and the cyclophosphamide, adriamycin, vincristine,
and prednisolone (CHOP) regimen. However, the treatment for chemorefractory primary splenic DLBCL remains
controversial. Therapeutic splenic irradiation (SI) might be a reasonable and possibly the only treatment option with
curative intention for patients with chemorefractory primary splenic DLBCL. However, the efficacy and safety of
therapeutic SI are unclear. Herein, we present the case of a primary splenic DLBCL patient who was refractory to
multiple chemotherapy regimens but achieved complete remission after administration of therapeutic SI. However, his
condition was complicated with severe gastric variceal bleeding due to splenic venous thrombosis, which was
successfully treated via splenectomy and short gastric vein ligation. On the basis of our findings, we concluded that the
splenic venous thrombosis-induced gastric variceal bleeding was a rare but life-threatening adverse effect of the
therapeutic SI administered for primary splenic DLBCL. Surgical intervention involving splenectomy and short gastric
vein ligation is mandatory and should be performed as soon as possible for such patients.
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Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon subtype of non-Hodgkin’s lymphoma, accounting for
approximately 30% of cases [1]. A combination of rituximab
(R) and the cyclophosphamide, adriamycin, vincristine, and
prednisolone (CHOP) regimen has become the standard
treatment for DLBCL because it greatly improves the out-
come of patients with this disease, especially of young
patients in the low-risk group [2]. Primary splenic DLBCL
is a rare clinical condition, for which the treatment option
generally involves six to eight cycles of chemotherapy with* Correspondence: chuchu0419.lin@gmail.com
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reproduction in any medium, provided the orthe R-CHOP regimen [3]. Furthermore, Iriyama et al. [4]
reported the case of a primary splenic DLBCL patient who
was successfully treated by splenectomy followed by three
cycles of chemotherapy with the R-CHOP regimen, sug-
gesting that surgery followed by abbreviated cycles of
chemotherapy could be an effective alternative treatment
for this disease. For patients who are refractory to chemo-
therapy or are inoperable, therapeutic splenic irradiation
(SI) might be a reasonable and possibly the only treatment
option with curative intention. However, the efficacy and
safety of SI in treating primary splenic DLBCL remain un-
certain and need further investigation. Herein, we present
the case of a primary splenic DLBCL patient who was re-
fractory to multiple chemotherapy regimens. Complete re-
mission was achieved using therapeutic SI. However, his
condition was complicated with severe gastric variceal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was successfully treated via splenectomy and short gastric
vein ligation.
Case presentation
A 32-year-old man who was a hepatitis B carrier with
Child-Pugh A liver cirrhosis presented with abdominal
fullness of three-month duration. Abdominal computed
tomography showed the presence of a large mass over
his spleen and adjacent lymph nodes (Figure 1). Labora-
tory examinations for complete blood count yielded nor-
mal results (white blood cell count: 6100/mm3, normal
range: 4000 to 8000/mm3; hemoglobin level: 12.7 g/dL,
normal range: 12 to 16 g/dL; platelet count: 319000/
mm3, normal range: 140000 to 400000/mm3; neutrophil:
65.3%; lymphocyte: 25.2%). The patient’s liver and renal
functions were within the normal ranges. However, the
level of lactate dehydrogenase was elevated (401 U/L,
normal range: 140 to 200 U/L). Examinations for detect-
ing coagulopathy yielded normal prothrombin time
(10.8 s, normal range: 9.5 to 11.7 s), activated partial
thromboplastin time (29.6 s, normal range: 24.3 to
32.7 s), protein C level (95.3%, normal range: 70 to
140%), protein S level (134%, normal range: 67 to 132%),
and antithrombin III level (111%, normal range: 80 to
120%). Exploratory laparotomy and biopsy confirmed
the diagnosis of DLBCL, which was immunohistochemi-
cally positive for CD20 and bcl6 but negative for CD3,
CD30 and bcl2. The Ki-67 index was 80%. The tumor
was staged as stage IIX because of the absence of bone
marrow and chest involvement. The age-adjusted Inter-
national Prognostic Index score was 2 [5].
The patient underwent six cycles of chemotherapy
with the R-CHOP regimen; however, positron emission
tomography (PET) and computed tomography detected
a residual tumor over the spleen after therapy comple-
tion. The patient underwent autologous hematopoieticFigure 1 Computed tomography scan of the abdomen showed
a large mass over the spleen and adjacent lymph nodes.stem cell harvest after high-dose cyclophosphamide
mobilization (2000 mg/(m-2d-1) for 2 d); however, this
procedure was not successful. Salvage chemotherapy in-
volving two cycles of etoposide, cisplatin, methylpredni-
solone, and cytarabine (ESHAP) regimen was
administered, but a residual tumor was still detected
over his spleen via PET and computed tomography one
month after the last ESHAP treatment. Subsequently,
therapeutic SI comprising 2400 cGy in 15 fractions was
administered. One month later, the patient developed
upper gastrointestinal bleeding. Upper gastrointestinal
endoscopy showed large gastric varices (GVs) with a red
color sign (Figure 2) but the ultrasonography could not
detect the splenic vein, which indicated the presence of
SVT. Abdominal computed tomography further con-
firmed this diagnosis (Figure 3). Sclerotherapy by locally
injecting N-butyl-2-cyanoacrylate could not stop the
gastric variceal bleeding; therefore, we performed splen-
ectomy and short gastric vein ligation. Pathological
examination of the dissected spleen showed extensive
necrosis, an organizing thrombus in the splenic vein,
and no viable tumor cells. After surgical intervention,
the GVs regressed completely, and the patient has been
in complete remission for more than one year.
Conclusions
Although the R-CHOP regimen has become the stand-
ard front-line treatment for DLBCL [6], the treatment
for patients who are refractory to the R-CHOP regimen
remains unclear. Salvage chemotherapy, autologous
hematopoietic stem cell transplantation, or radiotherapy
can be used as a therapeutic option for these patients
[7]. Because our patient was refractory to salvage
chemotherapy with the ESHAP regimen and autologousFigure 2 Upper gastrointestinal endoscopy image showed
large gastric varices with a red color sign.
Figure 3 Abdominal computed tomography scan showed a
filling defect in the splenic vein (arrow), indicating thrombosis
formation.
Lin et al. World Journal of Surgical Oncology 2012, 10:150 Page 3 of 4
http://www.wjso.com/content/10/1/150stem cell harvest was not successful, therapeutic SI was
a reasonable and probably the only curative treatment
for this patient. However, studies on the efficacy and ad-
verse effects of therapeutic SI for primary splenic
DLBCL are still required.
SI is a rarely used therapy. It is generally used for pro-
viding symptomatic relief to patients with chronic
lymphoid leukemia or myeloproliferative neoplasm-
related massive splenomegaly [8]. A palliative SI dose
mostly ranges between 400 cGy and 1000 cGy with only
slight toxicity [9]. Nevertheless, the optimal dose for
therapeutic SI for primary splenic DLBCL is still not
established clinically. Because doses of 3000 to 4000 cGy
are usually required for treating DLBCL, our patient
received therapeutic SI comprising a dose of 2400 cGy,
which was much higher than that administered in a pal-
liative setting. This treatment enabled the patient to
achieve complete remission, suggesting that therapeutic
SI comprising a dose of 2400 cGy could be effective for
patients with chemorefractory splenic DLBCL.
Although our patient achieved complete remission via
therapeutic SI, he suffered from a complication of SVT-
associated gastric variceal bleeding. SI is believed to in-
duce a broad range of both local and systemic effects,
which are not yet completely understood [9]. Most of
the reported adverse effects caused by SI are usually
well-tolerated, mainly limited to myelosuppression, and
are observed in palliative settings. However, the findings
of a study conducted by Elliott et al. [10] showed that,
after a single course of SI, prolonged, life-threatening
pancytopenia occurred in 26% (6/23) of myelofibrosis
patients. Moreover, three of the six patients in that co-
hort died of lethal sepsis or hemorrhage. Whether more
severe myelosuppression occurs in patients who undergo
therapeutic SI is not clear; however, it did not occur in
our patient. In contrast, our patient’s condition wascomplicated with SVT-associated gastric variceal bleed-
ing, which is life-threatening but rarely reported. The ac-
tual pathophysiology of SVT formation in patients who
undergo therapeutic SI is not yet completely understood.
Hypercoagulopathy disorders such as protein C, protein
S, and antithrombin III deficiencies were absent in our
patient, while treatment with chemotherapeutic agents
[11], endoscopic sclerotherapy [12], malignant lymph-
oma [13], and post-hepatitis B liver cirrhosis were the
factors applicable to our patient. The aforementioned
conditions and factors can be risk factors for SVT for-
mation in patients receiving SI.
In terms of treatment options for SVT-associated gas-
tric variceal bleeding, balloon-occluded retrograde trans-
venous obliteration [14] and splenectomy with short
gastric vein ligation could be both effective. Unfortu-
nately, balloon-occluded retrograde transvenous obliter-
ation was not available in our institution. In addition,
our findings suggest that splenectomy with short gastric
vein ligation should be mandatory when SVT-associated
gastric variceal bleeding occurs after therapeutic SI.
In summary, therapeutic SI could be an effective treat-
ment for chemorefractory primary splenic DLBCL. How-
ever, SVT-associated gastric variceal bleeding could be a
probable but life-threatening adverse effect of this treat-
ment. Surgical intervention involving splenectomy and
short gastric vein ligation should be performed as soon
as possible for such patients.
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